Literature DB >> 33990907

Fibrosis in hypertrophic cardiomyopathy: role of novel echo techniques and multi-modality imaging assessment.

Efstathios D Pagourelias1, Georgios M Alexandridis2, Vassilios P Vassilikos2.   

Abstract

Hypertrophic cardiomyopathy (HCM) represents one of the primary cardiomyopathies and may lead to heart failure and sudden cardiac death. Among various histologic features of the disease examined, assessment of myocardial fibrosis may offer valuable information, since it may be considered the common nominator for all HCM connected complications. Late gadolinium-enhanced cardiac magnetic resonance (LGE-CMR) has emerged as the reference noninvasive method for visualizing and quantifying myocardial fibrosis in patients with HCM. T1 mapping, a promising new CMR technique, may provide an advantage over conventional LGE-CMR, by permitting a more valid quantification of diffuse fibrosis. On the other hand, echocardiography offers a significantly more portable, affordable, and easily accessible solution for the study of fibrosis. Various echocardiographic techniques ranging from integrated backscatter and contrast-enhanced ultrasound to two- (2D) or three-dimensional (3D) deformation and shear wave imaging may offer new insights into substrate characterization in HCM. The aim of this review is to describe thoroughly all different modalities that may be used in everyday clinical practice for HCM fibrosis evaluation (with special focus on echocardiographic techniques), to concisely present available evidence and to argue in favor of multi-modality imaging application. It is essential to understand that the role of various imaging modalities is not competitive but complementary, since the information provided by each one is necessary to illuminate the complex pathophysiologic pathways of HCM, offering a personalized approach and treatment in every patient.
© 2021. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Deformation imaging; Fibrosis; Hypertrophic cardiomyopathy; Late gadolinium enhancement

Mesh:

Substances:

Year:  2021        PMID: 33990907     DOI: 10.1007/s10741-020-10058-6

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN: 1382-4147            Impact factor:   4.214


  70 in total

1.  Investigation of global and regional myocardial mechanics with 3-dimensional speckle tracking echocardiography and relations to hypertrophy and fibrosis in hypertrophic cardiomyopathy.

Authors:  Jose Angel Urbano-Moral; Ethan J Rowin; Martin S Maron; Andrew Crean; Natesa G Pandian
Journal:  Circ Cardiovasc Imaging       Date:  2013-11-25       Impact factor: 7.792

2.  Distinct Subgroups in Hypertrophic Cardiomyopathy in the NHLBI HCM Registry.

Authors:  Stefan Neubauer; Paul Kolm; Carolyn Y Ho; Raymond Y Kwong; Milind Y Desai; Sarahfaye F Dolman; Evan Appelbaum; Patrice Desvigne-Nickens; John P DiMarco; Matthias G Friedrich; Nancy Geller; Andrew R Harper; Petr Jarolim; Michael Jerosch-Herold; Dong-Yun Kim; Martin S Maron; Jeanette Schulz-Menger; Stefan K Piechnik; Kate Thomson; Cheng Zhang; Hugh Watkins; William S Weintraub; Christopher M Kramer
Journal:  J Am Coll Cardiol       Date:  2019-11-12       Impact factor: 24.094

Review 3.  Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy.

Authors:  Ali J Marian; Eugene Braunwald
Journal:  Circ Res       Date:  2017-09-15       Impact factor: 17.367

4.  Increased extent of myocardial fibrosis in genotyped hypertrophic cardiomyopathy with ventricular tachyarrhythmias.

Authors:  Takashi Fujita; Tetsuo Konno; Junichiro Yokawa; Eiichi Masuta; Yoji Nagata; Noboru Fujino; Akira Funada; Akihiko Hodatsu; Masa-aki Kawashiri; Masakazu Yamagishi; Kenshi Hayashi
Journal:  J Cardiol       Date:  2014-11-14       Impact factor: 3.159

5.  2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).

Authors:  Perry M Elliott; Aris Anastasakis; Michael A Borger; Martin Borggrefe; Franco Cecchi; Philippe Charron; Albert Alain Hagege; Antoine Lafont; Giuseppe Limongelli; Heiko Mahrholdt; William J McKenna; Jens Mogensen; Petros Nihoyannopoulos; Stefano Nistri; Petronella G Pieper; Burkert Pieske; Claudio Rapezzi; Frans H Rutten; Christoph Tillmanns; Hugh Watkins
Journal:  Eur Heart J       Date:  2014-08-29       Impact factor: 29.983

6.  Prognostic value of the collagen volume fraction in hypertrophic cardiomyopathy.

Authors:  Edmundo Arteaga; Aloir Queiroz de Araújo; Mauricio Bernstein; Felix J A Ramires; Barbara Maria Ianni; Fabio Fernandes; Charles Mady
Journal:  Arq Bras Cardiol       Date:  2009-03       Impact factor: 2.000

7.  The value of cardiac magnetic resonance and distribution of late gadolinium enhancement for risk stratification of sudden cardiac death in patients with hypertrophic cardiomyopathy.

Authors:  Mariusz Klopotowski; Krzysztof Kukula; Lukasz A Malek; Mateusz Spiewak; Magdalena Polanska-Skrzypczyk; Jacek Jamiolkowski; Maciej Dabrowski; Rafal Baranowski; Anna Klisiewicz; Mariusz Kusmierczyk; Anna Jasinska; Ewelina Jarmus; Mariusz Kruk; Witold Ruzyllo; Adam Witkowski; Lidia Chojnowska
Journal:  J Cardiol       Date:  2015-09-09       Impact factor: 3.159

8.  Characterization of hypertrophic cardiomyopathy according to global, regional, and multi-layer longitudinal strain analysis, and prediction of sudden cardiac death.

Authors:  Marie-Philippe Vergé; Hubert Cochet; Amélie Reynaud; Lucas Morlon; Jérôme Peyrou; Cécile Vincent; Caroline Rooryck; Philippe Ritter; Stéphane Lafitte; Patricia Réant
Journal:  Int J Cardiovasc Imaging       Date:  2018-02-27       Impact factor: 2.357

Review 9.  Hypertrophic cardiomyopathy: Can the noninvasive diagnostic testing identify high risk patients?

Authors:  Li Zhang; Obinna Mmagu; Liwen Liu; Dayuan Li; Yuxin Fan; Adrian Baranchuk; Peter R Kowey
Journal:  World J Cardiol       Date:  2014-08-26

10.  Diffuse interstitial fibrosis assessed by cardiac magnetic resonance is associated with dispersion of ventricular repolarization in patients with hypertrophic cardiomyopathy.

Authors:  David Hurtado-de-Mendoza; Celia P Corona-Villalobos; Iraklis Pozios; Jorge Gonzales; Yalda Soleimanifard; Sanjay Sivalokanathan; Diego Montoya-Cerrillo; Styliani Vakrou; Ihab Kamel; Wilfredo Mormontoy-Laurel; Ketty Dolores-Cerna; Jacsel Suarez; Sergio Perez-Melo; David A Bluemke; Theodore P Abraham; Stefan L Zimmerman; M Roselle Abraham
Journal:  J Arrhythm       Date:  2016-11-19
View more
  3 in total

1.  Predictive Value of Echocardiographic Strain for Myocardial Fibrosis and Adverse Outcomes in Autoimmune Diseases.

Authors:  Fuwei Jia; Xiao Li; Dingding Zhang; Shu Jiang; Jie Yin; Xiaojin Feng; Yanlin Zhu; Yingxian Liu; Yuanyuan Zhu; Jinzhi Lai; Huaxia Yang; Ligang Fang; Wei Chen; Yining Wang
Journal:  Front Cardiovasc Med       Date:  2022-02-21

2.  Case Report: A Chinese Family of Hypertrophic Cardiomyopathy Caused by a Novel Splicing Mutation in the FLNC Gene.

Authors:  Chunhui Huang; Yonghong Zheng; Wei Zhang; Zhigang Chen; Zhixin Huang; Yuan Fang
Journal:  Front Genet       Date:  2022-06-20       Impact factor: 4.772

Review 3.  Detection of myocardial fibrosis: Where we stand.

Authors:  Leyi Zhu; Yining Wang; Shihua Zhao; Minjie Lu
Journal:  Front Cardiovasc Med       Date:  2022-09-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.